EBT‑101 enters phase 1/2 HIV trial

CRISPR for HIV is the kind of idea that sounds almost too clean. Find the viral DNA hiding inside human cells, cut it out, and maybe you no longer need lifelong antiretroviral therapy. That is the promise behind EBT-101. But the actual news here is more grounded than the title suggests — this program is not just starting anymore. Its first human phase 1/2a trial has already run, enrolled 6 participants, and was marked completed on ClinicalTrials.gov in November 2024. (clinicaltrials.gov) ### What is EBT-101, exactly? EBT-101 is an in vivo CRISPR therapy — meaning the gene editor is delivered directly into the body, not used on cells outside the body and then reinfused. Excision designed it as a one-time intravenous treatment for people with HIV-1 who already have undetectable virus on stable ART. The basic trick is multiplex editing: guide RNAs direct the Cas9 system to more than one spot in the integr(clinicaltrials.gov)cked. (clinicaltrials.gov) ### Why is HIV the hard version? The problem is latency. HIV does not just circulate in blood — it inserts its DNA into long-lived cells and forms reservoirs that standard drugs cannot eliminate. ART is very good at stopping active replication, but once treatment stops, virus can rebound from those hidden copies. So EBT-101 is aimed at the part current medicine leaves behind. (clinicaltrials.gov)s was a first-in-human, open-label, single-ascending-dose study. Participants got one IV infusion on Day 1. The main goal was safety and tolerability. Secondary goals included biodistribution and immunogenicity — basically, where the therapy went in the body and how the immune system reacted. The protocol also allowed eligible participants to be assessed for an analytical treatm(clinicaltrials.gov)on of asking: does virus stay down if ART is paused? (clinicaltrials.gov) ### So did it cure anyone? Not from the public data we have. Excision’s 2023 and 2024 updates emphasized that EBT-101 met the primary safety endpoint and showed biodistribution, but they did not present a clean “functional cure” result. In the first reported cohort, there were no serious adverse events or dose-limiting toxicities, and all adverse events were described as mild and reversible. That is meaningful, but it (clinicaltrials.gov)ressed off therapy. (biospace.com) ### Why does safety dominate the story? Because this is systemic CRISPR. The editor is being sent through the body, not into one easy-to-watch tissue. That raises the usual gene-editing worries — off-target cuts, immune reactions, and delivery to the wrong places. The first job of a study like this is proving the platform is tolerable in real people. In that sense, EBT-101 seems to have done the conservative thing a first trial is supposed to do. (biospace.com) ### What made researchers think this was worth trying? The preclinical case was that an AAV9-delivered CRISPR construct could reach viral reservoir tissues after a single IV infusion in SIV-infected macaques. In that animal work, researchers reported broad biodistribution, evidence of in vivo proviral editing, and no detected off-target effects or abnormal pathology at tested doses. That does not guarantee human efficacy, but it explains why the company pushed into the clinic. (nature.com) ### What changed versus the earlier hype? The early framing was “first CRISPR HIV cure trial.” The more accurate framing now is narrower — first-in-human evidence that this kind of in-body CRISPR approach can be administered with an acceptable early safety profile. That is still important. But it moves the field from concept to feasibility, not from HIV treatment to HIV cure. (clinicaltrials.gov)it pushed a bold idea into humans and got through the first gate. The catch is that the first gate was safety. For people hoping for a one-shot cure, the story is still unfinished. (clinicaltrials.gov)